United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,894,849.68. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total transaction of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total transaction of $5,778,900.00.
• On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00.
• On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total transaction of $5,615,000.00.
• On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total transaction of $5,931,700.00.
• On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $535.90, for a total transaction of $5,359,000.00.
• On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00.

United Therapeutics Trading Up 1.4%

United Therapeutics stock opened at $588.38 on Friday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $607.89. The firm has a market capitalization of $25.79 billion, a price-to-earnings ratio of 21.09, a P/E/G ratio of 1.65 and a beta of 0.75. The firm has a 50 day simple moving average of $526.73 and a 200 day simple moving average of $489.49.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $6.19 EPS. On average, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Unusual bullish options flow — Traders bought 15,930 UTHR call options on Friday (about a 665% jump versus average call volume), indicating speculative or hedged bullish positioning that can amplify near-term upside or volatility.
• Positive Sentiment: Analyst target increases and constructive coverage — Multiple firms have raised price targets recently (examples cited include Morgan Stanley, Oppenheimer, BofA and RBC) and the consensus remains a “Moderate Buy” with an average target near $601.50, supporting positive investor sentiment. Analyst Coverage & MarketBeat Summary
• Neutral Sentiment: Small CEO sale disclosed — CEO Martine Rothblatt sold 75 shares (March 13) for roughly $40k; the size is immaterial to overall ownership and is unlikely on its own to drive stock direction. InsiderTrades Alert
• Neutral Sentiment: Institutional/hedge fund activity — Several funds adjusted positions (some added, some trimmed); UTHR remains heavily institutionally owned (~94%), which tends to moderate retail-driven swings. MarketBeat: Insider & Institutional Activity
• Negative Sentiment: Material insider selling by CEO — Martine Rothblatt sold 9,500 shares on April 15 (~$5.5M at ~$580.36), a significant reduction in her reported holding per filings; large insider sales can be perceived negatively by investors. SEC Filing: CEO Sale
• Negative Sentiment: Large EVP sale — EVP Paul A. Mahon sold 8,300 shares on April 16 for roughly $4.79M, a meaningful insider disposition that may pressure sentiment if more insider sales follow. SEC Filing: EVP Sale

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on UTHR shares. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 31st. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, TD Cowen boosted their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $601.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC purchased a new position in United Therapeutics in the fourth quarter worth $26,000. Activest Wealth Management grew its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the fourth quarter worth $31,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.